Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
5.40
+0.06 (1.12%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Astria Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Net Income
-94.26-72.89-51.83-194.91-37.3
Upgrade
Asset Writedown & Restructuring Costs
---164.61-
Upgrade
Loss (Gain) From Sale of Investments
-5.61-0.09---
Upgrade
Stock-Based Compensation
13.046.314.553.361.39
Upgrade
Other Operating Activities
1.070.631.10.660.06
Upgrade
Change in Accounts Payable
2.810.73-0.77-1.970.35
Upgrade
Change in Other Net Operating Assets
1.74-3.143.41-1.913.02
Upgrade
Operating Cash Flow
-81.21-68.45-43.53-30.15-32.49
Upgrade
Capital Expenditures
-0.33-0.03-0.09-0.02-0.03
Upgrade
Cash Acquisitions
---6.47-
Upgrade
Investment in Securities
-191.54135.08-167.04-196.33
Upgrade
Investing Cash Flow
-191.86135.05-167.13-12.566.3
Upgrade
Issuance of Common Stock
157.288.4144.72104.2840.86
Upgrade
Financing Cash Flow
157.288.4144.72104.2840.86
Upgrade
Net Cash Flow
-115.87155.01-65.9461.5814.68
Upgrade
Free Cash Flow
-81.54-68.47-43.62-30.17-32.52
Upgrade
Free Cash Flow Per Share
-1.45-2.27-2.98-3.38-10.63
Upgrade
Levered Free Cash Flow
-52.58-36.52-25.02-16.71-18.79
Upgrade
Unlevered Free Cash Flow
-52.58-36.52-25.02-16.71-18.79
Upgrade
Change in Net Working Capital
-4.430.42-3.951.08-3.25
Upgrade
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q